Tariff Escalation and Invasive Species Risk



Ie


αK


α-z


τI
θτIFG


+ zIPG
α-zI


τ -

τ IFG


τI
θτIFG


θ

θ-1


τI


α-zI


(18)


Parameter zI is assumed to be small enough such that α> zI . This leads to a condition for both

domestic and imported input to be positive as follows:

zDIe<τ-z IFGe<αDIe,

IIIFG

where DIe = DI * and IFGe = IFG* as specified in the previous section. The latter condition
defines some relation between tariff factors, frequency of occurrence, and cost parameters.

As in the previous case in section 3.2, the crux of the welfare analysis lies in the input
market, as allocative efficiency increases unambiguously in the output market. The surplus from
the derived demand
DI can be measured in terms of the DFG producer surplus by integrability
and can be abstracted from. Hence, welfare consequences in the input market hinge on the
producer surplus for input
D and the deadweight loss associated with the DI derived demand:

we = 0.5De [r -z,Γ z',G1


IFGe]- /lDId(τ,τFG)dτ-DIe

= 0.5De [τ, - z,Γ - z,roIFGe ^ - K (θτ,ro )' ")
II    IFG           IFG


'θ - ' τ θ/(θ-')
θ θ i


+ Ti 17cθ-')


(19)


How does the equilibrium look after the reform? We now reduce the tariff escalation by
reducing
tIFG to tINFGtIFG and keeping tI constant. Denote the new equilibrium by a superscript
(
ee). The equilibrium levels of FGee , DFGee , IFG ee , and DIee remain the same as those in the
initial equilibrium (**) in the situation with absence of invasive species risks associated with
imported processed good.

6 we use D = τι - zPG1FG z Dl , and Г = aDI + zPG1FG - τι


α-zI


α-zI


16




More intriguing information

1. The name is absent
2. Voting by Committees under Constraints
3. Behavioural Characteristics and Financial Distress
4. The name is absent
5. The name is absent
6. Staying on the Dole
7. The name is absent
8. AGRIBUSINESS EXECUTIVE EDUCATION AND KNOWLEDGE EXCHANGE: NEW MECHANISMS OF KNOWLEDGE MANAGEMENT INVOLVING THE UNIVERSITY, PRIVATE FIRM STAKEHOLDERS AND PUBLIC SECTOR
9. The name is absent
10. Cyber-pharmacies and emerging concerns on marketing drugs Online